Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

256.25 1.51 +0.59%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
22.89 22.22 21.37 19.56

+8 more quarters

P/S ratio
2.17 2.04 1.91 1.75
P/FCF ratio
18.65 17.44 16.26 14.17
P/Operating CF
41.96 39.41 77.55 41.42
P/B ratio
3.22 3.01 2.81 2.67
EV/Sales
2.57 2.47 2.38 2.22
EV/EBITDA
13.17 12.92 12.27 11.53
EV/FCF
22.10 21.16 20.23 18.04
Current Ratio
1.70 1.59 1.18 1.04
Net Debt/EBITDA
7.59 8.29 9.64 9.89
Debt/Equity
0.70 0.72 0.74 0.79
Earnings Yield
4.37% 4.50% 4.68% 5.11%
Free Cash Flow Yield
5.36% 5.73% 6.15% 7.06%
Free Cash Flow per Share
4.05 4.14 1.49 2.77
Book value per Share
72.27 70.44 69.69 64.92
Free Cash Flow
445.00 459.00 164.00 307.00
EV/EBIT
17.64 17.51 16.67 15.75
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026